Guilingji Capsule for Mild-to-moderate Cognitive Impairment

Cognitive Dysfunction Clinical Trial

Official title:

Efficacy and Safety of Guilingji Capsule in Older Adults With Mild-to-Moderate Cognitive Impairment (Kidney and Marrow Deficiency Pattern)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03647384
• Other study ID #: 2018XLA039-2
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: August 22, 2018
• Est. completion date: December 2019

Study information

• Verified date: August 2018
• Source: Xiyuan Hospital of China Academy of Chinese Medical Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is aiming to evaluate the efficacy and safety of Guilingji capsule in older adults with mild-to-moderate cognitive impairment who diagnosed as the kidney and marrow deficiency pattern in TCM. A total of 348 participants are evenly assigned to two arms. In the intervention arm, participants receive Guilingji capsule and Ginko Biloba Extract mimetic in combination, while the other arm will receive Ginko Biloba Extract tablet with Gulingji mimetic.

Description:

This study is a multi-center, randomized, positive control, noninferiority clinical trials. Experimental arm (174 cases) take 0.6 g of Gulingji capsules once a day and 19.2 mg of Ginko Biloba Extract mimetic three times a day. Active Comparator arm (174 cases) should take 0.6 g of Gulingji mimetic once a day and 19.2 mg of Ginko Biloba Extract tablet three times a day. The intervention lasted for 24 weeks. Clinical researchers, participants and statisticians are blinded to the treatment assignment throughout the study. Co-primary efficacy endpoints are change from baseline to week 12 and 24 in Mini-Mental State Examination score and Montreal Cognitive Assessment (MoCA) total score.Change from baseline to week 12 and 24 in Clinical Dementia Rating score, Alzheimer's Disease Assessment Scale-Cognitive subscale score, Activities of Daily Living, and Chinese Medicine Symptom Scale scoreare additional endpoints. Prespecified secondary biomarker endpoint is change from baseline in the serum level of acetylcholine and acetylcholinesterase at week 24.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 348
• Est. completion date: December 2019
• Est. primary completion date: December 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 60 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Aged between 60 and 85 years old

2. With a disease course = 6 months and confirmed by others

3. Mini-Mental State Examination (MMSE) score between 10 and 26, or MMSE score >26 but Montreal Cognitive Assessment (MoCA) score<26

4. Meeting the diagnostic criteria of mild-to-moderate cognitive impairment

5. Meeting the diagnostic criteria of kidney deficiency pattern in Traditional Chinese medicine

6. Screening visit brain MRI and CT scan consistent with the diagnosis of mild-to-moderate cognitive impairment

7. Adequate visual and auditory abilities to perform all aspects of the cognitive and functional assessments

8. Received a primary and/or a higher education

9. Lives at home with appropriate caregiver capable of accompanying the subject on all clinic visits, or community dwelling with caregiver capable of accompanying the subject on all clinic visits and visiting with the subject approximately 5 times per week for the duration of the study

10. Signed and dated written informed consent. The subject's caregiver must also consent to participate in the study

Exclusion Criteria:

1. Significant neurological disease, other than AD MCI and VaD, that may affect cognition, such as the Parkinson's disease, the Huntington's disease, normal pressure hydrocephalus, brain tumors, progressive supra-nuclear palsy, epilepsy, chronic subdural hematoma and multiple sclerosis, history of severe head trauma with persistent neurological deficits or known abnormal brain structure

2. Thyroid disease, vitamin B12 or folic acid deficiency, severe anemia or malnutrition, serious heart, liver, lung, kidney and other organ diseases that may affect the cognitive function

3. Allergic to Ginkgo products

4. Use of any other medications with the potential to affect cognition

5. Current presence of a clinically important major psychiatric disorder or symptom

6. Alcohol addiction, or long-term use of antipsychotic drugs, or a history of severe head trauma

7. Cannot complete with cognitive function examines.

Related Conditions & MeSH terms

• Cognitive Dysfunction

Intervention

Drug:
• Gulingji capsules
Patients take 0.6g of Gulingji capsules, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract mimetic three times a day. Treatment lasts for 24 weeks.
• Ginko Biloba Extract tablet
Patients take 0.6g of Gulingji mimetic, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract tablet three times a day. Treatment lasts for 24 weeks.

Locations

Country	Name	City	State
China	Li Hao	Beijing	Beijing

Sponsors (12)

Lead Sponsor

Collaborator

Xiyuan Hospital of China Academy of Chinese Medical Sciences

Beijing Hospital, Beijing Shijitan Hospital, Beijing Xuanwu Traditional Chinese Medicine Hospital, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Huadong Hospital, Longhua Hospital, Peking University First Hospital, Shaanxi Hospital of Traditional Chinese Medicine, Shanxi Dayi Hospital, The Affiliated Hospital of Shandong University of TCM, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Change From Baseline in Mini-Mental State Examination (MMSE) Total Score at Week 12 and 24	MMSE is a 30-point questionnaire and contains items assessing orientation, memory, attention and calculation, naming and visuospatial skills of patients.	Baseline,12th week±3 days, 24th week±3 days
Primary	The Change From Baseline in Montreal Cognitive Assessment (MoCA) Total Score at Week 12 and 24	MoCA is a 30-point questionnaire and evaluates orientation, executive function, language ability, short-term memory, attention and visuospatial ability.	Baseline,12th week±3 days, 24th week±3 days
Secondary	The Change From Baseline in Clinical Dementia Rating (CDR) Total Score at Week 12 and 24	The CDR test is a numeric scale used to quantify the severity of symptoms of dementia. It sums 6 clinical ratings: 1) memory, 2) orientation, 3) judgment and problem solving, 4) involvement in community affairs, 5) home and hobbies, and 6) personal care based on the CDR interview. The CDR includes discussions with the participant and caregiver using a structured format. CDR total score range is 0 (least impairment) to 18 (most impairment); a negative change from baseline indicates an improvement.	Baseline,12th week±3 days, 24th week±3 days
Secondary	The Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Total Score at Week 12 and 24	The ADAS-Cog is a multi-item, objective measure of cognitive function. Analysis of the ADAS-Cog for this study is based upon an 12 item score from the following items 1) word recall task, 2) naming objects and fingers, 3) following commands, 4) constructional praxis, 5) ideational praxis, 6) orientation, 7) word recognition, 8) remembering test instructions, 9) spoken language ability, 10) word finding difficulty in spontaneous speech, 11) comprehension, and 12) attention during the test. The ADAS-Cog ranged from 0 to 75 points, with higher scores indicating a greater degree of impairment. A negative change from baseline indicates a decrease in cognitive impairment.	Baseline,12th week±3 days, 24th week±3 days
Secondary	The Change From Baseline in Activities of Daily Living (ADL) Total Score at Week 12 and 24	The ADL is a test used in healthcare to evaluate the people's daily self care activities.	Baseline,12th week±3 days, 24th week±3 days
Secondary	The Change From Baseline in The Chinese Medicine Symptom Scale (CM-SS) Total Score at Week 12 and 24	The CM-SS is a tool, designed according to the Guiding Principles of Clinical Research on New Drugs of Traditional Chinese Medicine issued in 2002, to evaluate the effects of treatments on Traditional Chinese medicine patterns (here refers to kidney deficiency pattern). Scoring is mainly based on some typical TCM symptoms, such as tongue coating and pulse.	Baseline,12th week±3 days, 24th week±3 days
Secondary	The Change From Baseline in The Serum Level of Acetylcholine and Acetylcholinesterase at Week 24	Acetylcholine and acetylcholinesterase are potential circulatory biomarkers of cognitive dysfunction.	Baseline, 24th week±3 days